mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2025-2-98-101mrj-1746Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОпыт применения селективного ингибитора Янус-киназ упадацитиниба у пациента с псориатическим артритом (клиническое наблюдение)The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)https://orcid.org/0000-0003-4616-1259ЛушпаеваЮ. А.LushpaevaYu. A.

Юлия Арнольдовна Лушпаева

625023, Тюмень, ул. Одесская, 54

Yulia Arnoldovna Lushpaeva

54, Odesskaya Street, Tumen 625023

lushpaevay@mail.ruФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава РоссииРоссияTumen State Medical University, Ministry of Health of RussiaRussian Federation20252204202519298101Copyright © Лушпаева Ю.А., 20252025Лушпаева Ю.А.Lushpaeva Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1746

Представлен пациент с псориатическим артритом (ПсА) и ладонно-подошвенным псориазом, резистентный к стандартной терапии, у которого после назначения упадацитиниба в дозе 15 мг/сут наблюдалось значительное снижение активности основного заболевания, а c 3-го месяца лечения достигнута ремиссия. В течение 6 мес терапии нежелательных явлений не отмечалось.

We describe a patient with psoriatic arthritis (PSA) and palmoplantar psoriasis, resistant to standard therapy, who observed a significant decrease in disease activity on the background of upadacitinib at a dose of 15 mg/day. Remission was achieved by the 3rd month of treatment. No adverse phenomena were observed within 6 months of treatment.

псориатический артритингибиторы Янус-киназупадацитиниббиологическая/таргетная терапияpsoriatic arthritisJanus kinase inhibitorsupadacitinibbiologic/targeted therapyReferencesФедеральные клинические рекомендации Псориаз артропатический. Псориатический артрит. 2024. https://cr.minzdrav.gov.ru/.Federal clinical guidelines Psoriatic Arthritis. 2024. https://cr.minzdrav.gov.ru/.Kimak A, Robak E, Makowska J, Wozniacka A. Psoriatic Arthritis: Development, Detection and Prevention: A Scoping Review. J Clin Med. 2023 Jun 5;12(11):3850. doi: 10.3390/jcm12113850.Kimak A, Robak E, Makowska J, Wozniacka A. Psoriatic Arthritis: Development, Detection and Prevention: A Scoping Review. J Clin Med. 2023 Jun 5;12(11):3850. doi: 10.3390/jcm12113850.Azuaga A, Ramirez J, Canete J. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci. 2023 Mar 3;24(5):4901. doi: 10.3390/ijms24054901.Azuaga A, Ramirez J, Canete J. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci. 2023 Mar 3;24(5):4901. doi: 10.3390/ijms24054901.Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024 May 15;83(6):706-719. doi: 10.1136/ard-2024-225531.Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024 May 15;83(6):706-719. doi: 10.1136/ard-2024-225531.Nash P, Richette P, Gossec L, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022 Aug 3;61(8): 3257-3268. doi: 10.1093/rheumatology/keab905.Nash P, Richette P, Gossec L, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022 Aug 3;61(8): 3257-3268. doi: 10.1093/rheumatology/keab905.Mease P, Lertratanakul A, Anderson J, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021 Mar;80(3):312-320. doi: 10.1136/annrheumdis-2020-218870. Epub 2020 Dec 3.Mease P, Lertratanakul A, Anderson J, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021 Mar;80(3):312-320. doi: 10.1136/annrheumdis-2020-218870. Epub 2020 Dec 3.Sarabia S, Ranjith B, Koppikar S, Wijerat ne D. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol. 2022 Sep 27;6(1):71. doi: 10.1186/s41927-022-00287-7.Sarabia S, Ranjith B, Koppikar S, Wijerat ne D. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol. 2022 Sep 27;6(1):71. doi: 10.1186/s41927-022-00287-7.Burmester GR, Stigler J, Rubbert-Roth A, et al. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun; 11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.Burmester GR, Stigler J, Rubbert-Roth A, et al. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun; 11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.Keeling S, Maksymowych W. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Rev Clin Immunol. 2021 Jul;17(7): 701-715. doi: 10.1080/1744666X.2021.1925541. Epub 2021 May 13.Keeling S, Maksymowych W. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Rev Clin Immunol. 2021 Jul;17(7): 701-715. doi: 10.1080/1744666X.2021.1925541. Epub 2021 May 13.Drosos A, Venetsanopoulou A, Voulgari P. Axial Spondyloarthritis: Evolving concepts regarding the disease's diagnosis and treatment. Eur J Intern Med. 2023 Nov:117:21-27. doi: 10.1016/j.ejim.2023.06.026. Epub 2023 Jul 5.Drosos A, Venetsanopoulou A, Voulgari P. Axial Spondyloarthritis: Evolving concepts regarding the disease's diagnosis and treatment. Eur J Intern Med. 2023 Nov:117:21-27. doi: 10.1016/j.ejim.2023.06.026. Epub 2023 Jul 5.Ritchlin C, Colbert R, Gladman D. Psoriatic Arthritis. N Engl J Med. 2017 May 25; 376(21):2097. doi: 10.1056/NEJMx170005.Ritchlin C, Colbert R, Gladman D. Psoriatic Arthritis. N Engl J Med. 2017 May 25; 376(21):2097. doi: 10.1056/NEJMx170005.Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019 Sep 20:8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1. eCollection 2019.Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019 Sep 20:8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1. eCollection 2019.Uppala R, Tsoi L, Harms P, et al. "Auto inflammatory psoriasis"– genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021 Feb;18(2):307-317. doi: 10.1038/s41423-020-0519-3. Epub 2020 Aug 19.Uppala R, Tsoi L, Harms P, et al. "Auto inflammatory psoriasis"– genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021 Feb;18(2):307-317. doi: 10.1038/s41423-020-0519-3. Epub 2020 Aug 19.

The authors declare that there are no conflicts of interest present.